Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.84 |
| ▸ | MAPT | P10636 | 6/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.84 |
| ▸ | TTR | P02766 | 4/20 | 0.84 |
| ▸ | LMNA | P02545 | 4/20 | 0.84 |
| ▸ | TP53 | P04637 | 4/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.84 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.67 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.61 |
| ▸ | TUBB | P07437 | 2/20 | 0.61 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.61 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.61 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.61 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.61 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.61 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.61 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.61 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808386 | 1.00 | MEN1 (0.84) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL1486827 | 0.93 | MEN1 (0.73) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL1486831 | 0.93 | MEN1 (0.73) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL2574065 | 0.93 | LMNA (0.77) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL2574064 | 0.93 | LMNA (0.77) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| Triacetylresveratrol SCHEMBL717980 | 0.91 | TTR (1.00) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| Triacetylresveratrol SCHEMBL717979 | 0.91 | TTR (1.00) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL16130494 | 0.91 | KDM4E (0.69) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL6847961 | 0.88 | KDM4E (0.81) | MEN1MAPTKMT2AKDM4ECYP3A4 | |
| SCHEMBL1810217 | 0.88 | KDM4E (0.81) | MEN1MAPTKMT2AKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111777577-A | Taxol derivative and application thereof in preparation of medicine for preventing and treating human malignant tumor | 天津仁雨生物科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-21 | — | — | US | disclosed |
| US-9040521-B2 | Methods and compositions for modulating tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-05-26 | — | — | US | disclosed |
| US-8841477-B2 | Sirtuin activating compounds and processes for making the same | BRIGHAM YOUNG UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-8748464-B2 | Use of SIRT1 activators or inhibitors to modulate an immune response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2496594-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | The J. David Gladstone Institutes (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120225864-A1 | Methods and Compositions for Modulating Tau Levels | THE J. DAVID GLADSTONE INSTITUTES | 2012-09-06 | — | — | US | disclosed |
| WO-2011056300-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | disclosed |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7714161-B2 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY (US) | 2010-05-11 | — | — | US | disclosed |
| WO-2009099643-A1 | USE OF SIRT1 ACTIVATORS OR INHIBITORS TO MODULATE AN IMMUNE RESPONSE | THE J. DAVID GLADSTONE INSTITUTES (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| EP-1753708-A4 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | MEN1 4151/4885MAPT 2086/4885KMT2A 510/4885 |
| US-20120225864-A1 | Methods and Compositions for Modulating Tau Levels | MAPT, NEFM, PSEN2 | MEN1 4397/4885MAPT 1/4885KMT2A 2108/4885 |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | MEN1 4151/4885MAPT 2086/4885KMT2A 510/4885 |
| US-20100185006-A1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND PROCESSES FOR MAKING THE SAME | SIRT1, SIRT2, SIRT3 | MEN1 3475/4885MAPT 4298/4885KMT2A 542/4885 |
| US-20160015733-A1 | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS | MAPT, NEFM, PSEN2 | MEN1 4397/4885MAPT 1/4885KMT2A 2108/4885 |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | RB1, SBK1, NADK | MEN1 3788/4885MAPT 4496/4885KMT2A 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.